The majority of patients with chronic myeloid leukaemia (CML) are willing to attempt treatment free remission – taking a 50:50 chance on a life free of the side effects associated with tyrosine kinase inhibitors. The Australian research found 81% of CML patients who have achieved a stable, deep molecular response with drugs such as imatinib ...
CML patients willing to take a risk for no side effects
By Mardi Chapman
4 Jul 2017